Cogent Biosciences, Inc. (COGT) investor relations documents from the company's IR site: 4 presentations, 21 press releases; latest deck 2026-05-12. Read in-app with summaries. First-party data.
May 2026 Corporate Presentation: Cogent Biosciences' May 2026 corporate presentation highlights positive pivotal trial results for bezuclastinib in GIST and systemic mastocytosis.
COGT overview · COGT earnings · COGT financials · COGT KPIs · COGT documents · COGT ownership · COGT peers
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.